DYRK1A and plasma cell myeloma: It also recently entered phase I/IIclinical trials for cholangiocarcinoma58 and multiple myeloma.6 The therapeuticpotential of CX-4945 arises due to its well-documented invitro and in vivo efficiency and is alsosupported by its desirable pharmacokinetic profile (long half-life,oral bioavailability, limited toxicity).59,60 Here, we show that CX-4945 strongly binds and inhibits DYRK1A andGSK3β.